| The Effects of Risperidone and Olanzapine on Thinking (NCT00108368) | US Department of Veterans Affairs | 2003-10-01 |
| Genetics of Symptomatology and Treatment Response in Psychotic Major Depression (NCT00691535) | Stanford University | 2003-10-01 |
| A Registry of Treatment Adherence for Patients With Schizophrenia (NCT00283517) | Janssen-Cilag, S.A. | 2003-09-01 |
| Enhancing the Prospective Prediction of Psychosis (NCT00291200) | Yale University | 2003-08-01 |
| Dutch Prediction of Psychosis Study (NCT00188981) | UMC Utrecht | 2003-06-01 |
| Psychosis: Early Detection, Intervention and Prevention (NCT01597141) | MaineHealth | 2003-05-01 |
| Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study (NCT00145444) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-03-01 |
| Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting (NCT00932529) | University of Bergen | 2003-02-01 |
| Medication Adherence in Older People With Psychosis (NCT00071604) | Veterans Medical Research Foundation | 2002-09-01 |
| A Comparative Study of New Medications for Psychosis in Adolescents (NCT00222495) | University of Minnesota | 2002-08-01 |
| RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice (NCT00458367) | Janssen Pharmaceutica N.V., Belgium | 2002-06-01 |
| Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder (NCT00236353) | Janssen, LP | 2002-05-01 |
| Critical Time Intervention in the Transition From Hospital to Community in People With Severe Mental Illness (NCT00621465) | New York State Psychiatric Institute | 2002-04-01 |
| CAFE Comparison of Atypicals in First Episode of Psychosis (NCT00034892) | AstraZeneca | 2002-03-01 |
| Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients (NCT00159770) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2001-11-01 |
| Indicated Prevention of Psychotic Disorders With Low-dose Lithium (NCT00202306) | Melbourne Health | 2001-11-01 |
| Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants (NCT00419146) | University Hospital, Aker | 2001-09-01 |
| A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. (NCT00034775) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2001-08-01 |
| A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients (NCT00249171) | Janssen Pharmaceutica N.V., Belgium | 2001-06-01 |
| The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder (NCT00044187) | Eli Lilly and Company | 2001-04-01 |
| A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder (NCT00236457) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2000-11-01 |
| Recovery Therapy Trial (NCT00239122) | Melbourne Health | 2000-06-01 |
| Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents (NCT00183612) | Massachusetts General Hospital | 2000-05-01 |
| A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia (NCT00249223) | Janssen Pharmaceutica N.V., Belgium | 2000-01-01 |
| A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia (NCT00253136) | Janssen, LP | 1999-11-01 |
| Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke (NCT00307203) | National Institute on Drug Abuse (NIDA) | 1998-08-01 |
| Treatment of Schizoaffective Disorder Using Mifepristone (NCT00725270) | Stanford University | 1998-04-01 |
| Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis (NCT00157313) | Bispebjerg Hospital | 1998-01-01 |
| A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia (NCT00249132) | Janssen, LP | |
| Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection (NCT00236548) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |